The incidence and predictors of non-gastrointestinal (GI) adverse events after colonoscopy are not well-understood.
Dr David Johnson and colleagues from Virginia, USA studied the effects of antithrombotic agents, cardiopulmonary comorbidities, and age on risk of non-GI adverse events after colonoscopy.
The team performed a retrospective longitudinal analysis to assess the diagnosis, procedure, and prescription drug codes in a United States commercial claims database.
Data from patients at increased risk were compared with data from 398,663 average-risk patients.
|Underlying infection may contribute towards corticosteroid nonresponse |
|Clinical Gastroenterology & Hepatology|
The researchers compared 51,932 patients at increased risk, examined by colonoscopy, with 51,932 matched patients at increased risk who did not undergo colonoscopy.
The team tracked cardiac, pulmonary, and neurovascular events 1–30 days after colonoscopy.
The researchers noted that 30 days after outpatient colonoscopy, non-GI adverse events were significantly higher in patients taking antithrombotic medications or those with pulmonary comorbidities vs average-risk patients, and in patients 60–69 years old or 70 years or older, compared with patients younger than 50 years.
The 30-day incidence of non-GI adverse events in patients at increased risk who underwent colonoscopy was also significantly higher than in matched patients at increased risk who did not undergo colonoscopy in the anticoagulant group, and in the chronic obstructive pulmonary disease.
Dr Johnson's team concludes, "Increased number of comorbidities and older age are associated with increased risk of non-GI adverse events after colonoscopy."
"These findings indicate the importance of determining comorbid risk and evaluating antithrombotic management before colonoscopy."